And even if patients’ survival was analysed only in the non-pCR group, we can find the tendency to have worse survival in cases with increased CD44+/CD24− or ALDH1+ tumour cell populations (P=0.127, 0.087, respectively; data not shown). This evidence concerns the gene CD44 and neoplasm.